Nedermaas Hightech Ventures
VC Fund
Maastricht, The Netherlands
Nedermaas Hightech Ventures is a VC fund in Maastricht focused on Biotechnology and Life Science. Nedermaas Ventures focuses on pre-seed and seed investment opportunities across a broad spectrum of high technology fields.Based in Maastricht, the Netherlands, we focus on start-up companies in, or willing to relocate to the Limburg region.Our goal is to help entrepreneurs achieve their maximum potential through investments and loans, aswell as advice, support and access to our network.Our investments typically range from 150.000 to 500.000 euro.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Nedermaas Hightech Ventures invests in
Stages Nedermaas Hightech Ventures invests in
Countries Nedermaas Hightech Ventures invests in
Investment Focus
Industry
- Biotechnology 4 (57%)
- Life Science 3 (43%)
- Genetics 2 (29%)
- Agriculture 2 (29%)
- Health Care 2 (29%)
Stage
- Funding Round 4 (57%)
- Seed 1 (14%)
- Series A 1 (14%)
- Venture - Series Unknown 1 (14%)
Country
- The Netherlands 5 (71%)
- France 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cristal Therapeutics is a pharmaceutical company developing a new class of nanomedicine based on its proprietary polymeric technologies. It aims to find valuable solutions for medical needs by creating superior drug products. Both new and existing drugs can be combined with Cristal Therapeutics Polymeric Technologies, shortly abbreviated as CriPec.CriPec-based products are versatile as a crystal and allow to improve the treatment of various diseases. | $13.6M / Venture - Series Unknown / Jan 19, 2017 | ||
| Cristal Therapeutics is a pharmaceutical company developing a new class of nanomedicine based on its proprietary polymeric technologies. It aims to find valuable solutions for medical needs by creating superior drug products. Both new and existing drugs can be combined with Cristal Therapeutics Polymeric Technologies, shortly abbreviated as CriPec.CriPec-based products are versatile as a crystal and allow to improve the treatment of various diseases. | $6.6M / Dec 15, 2014 | ||
| Enzypep designs and develops oligopeptides for pharmaceutical products. The Enzypep technology is expected to become the state-of-the-art in design and preparation of complex peptides. Compared with standard synthesis it results in pharmaceutical products with a much higher purity, at a much lower cost and in a sustainable,environmentally-friendly manner. It began operation in 2012, with its headquarters in Geleen in the Netherlands. | Jan 01, 2014 | ||
| Ekompany is a Dutch producer of coated mineral fertilisers (CRF) with sales operations in Western Europe and Far East. Their team of professionals possesses the latest knowledge across the chemical, agricultural and horticultural fields and have decades of experience in designing, producing and supplying specialty fertilisers supported by the rightadvice.Established in 2010, their unique production facility in Born was opened for production in September 2013. Ekompany has developed a patented coating process that is clean, safe, continuous and more energy efficient than existing ones. This way they can produce intelligent Controlled Release Fertilisers that are both technologically advanced and economical for wider use in agriculture and horticulture. Learn more about their Ekote portfolio which has proven its benefits in more than 200 field trials internationally. | $12.3M / Mar 06, 2013 | ||
| Phenospex provides digital solutions that capture crop data and convert it into actionable information, amplifying the effect of countless individuals and speeding up the transition to sustainable agriculture. They offer clever digital phenotyping solutions that include sensors, software, and full process automation. Their goal is to automate theprocess, turn data into action, and enable their clients to produce innovative agrochemicals and crops more quickly than ever before. | $549K / Seed / Dec 13, 2011 | ||
| BioActor develops proprietary health ingredients for use in functional foods, medical nutrition and dietary supplements. All these ingredients address chronic health concerns, such as diabetes,osteoporosis, cardiovascular disease, that would benefit from preventative measures through the diet. BioActor's product development strategy relies onthree simple tenets: a new health ingredient must be based on a patentable scientific discovery; it must be food grade from a natural and renewable source; and its health effect must be clinically proven. BioActor's first product, BONOLIVE, a first in class bone health ingredient that is clinically proven to stimulate bone producing cells, is a great example of this strategy and will be launched in the USA this year. BioActor successfully implemented its product development strategy by establishing alliances with top nutrition research institutes (e.g. INRA, CSIC, Maastricht University, UCL, Ghent University) and by establishing production partnerships with industrial players to shorten the path to market. | $2.2M / Series A / Jul 26, 2011 | ||
| CellMade develops and commercializes cell biology products and services: human-origin primary cells, co-culture models, customized cell isolation and characterization. CellMade also invests in its own R&D program using its CellInsight platform for identification of targets and biomarkers related to inflammatory pathologies. The company hasfacilities in Marseille (France) and at the Chemelot Campus. | $1.8M / Oct 01, 2010 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Nedermaas Hightech Ventures invest in?
Nedermaas Hightech Ventures invests primarily in Biotechnology, Life Science and Genetics startups, most often at Funding Round and Seed stage. Most of the 7 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Nedermaas Hightech Ventures last invest?
The most recent investment recorded for Nedermaas Hightech Ventures closed in Jan 2017. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
